Viridian Therapeutics, Inc./DE Restructuring Charges
Viridian Therapeutics, Inc./DE (VRDN) reported Restructuring Charges of $300.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2021-03-26
- Viridian Therapeutics, Inc./DE restructuring charges for the quarter ending 2020-12-31 was $9.00K, a 99.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE restructuring charges for the quarter ending 2020-09-30 was $100.00K.
- Viridian Therapeutics, Inc./DE restructuring charges for the quarter ending 2020-06-30 was $100.00K.
- Viridian Therapeutics, Inc./DE restructuring charges for the quarter ending 2020-03-31 was $119.00K.
- Viridian Therapeutics, Inc./DE restructuring charges for fiscal 2020 was $300.00K, a 85.00% decline from fiscal 2019.
- Viridian Therapeutics, Inc./DE restructuring charges for fiscal 2019 was $2.00M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 9 month as first filed | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $109.00K derived: sum of 2 quarters · filed 2021-03-26 | $209.00K derived: sum of 3 quarters · filed 2021-03-26 | $300.00K 10-K · filed 2021-03-26 | |||
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-12 | $200.00K derived: sum of 2 quarters · filed 2020-11-12 | $291.00K 10-Q · filed 2020-11-12 | $1.22M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-05 | $208.00K 10-Q · filed 2020-08-05 | $1.12M derived: sum of 3 quarters · filed 2020-08-05 | $1.12M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2020-03-31 | $119.00K 10-Q · filed 2020-05-08 | $1.02M derived: sum of 2 quarters · filed 2020-05-08 | $1.02M derived: sum of 3 quarters · filed 2020-11-12 | $1.02M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-12-31 | $900.00K 10-K · filed 2020-03-13 | $900.00K derived: sum of 2 quarters · filed 2020-11-12 | $900.00K derived: sum of 3 quarters · filed 2020-11-12 | $2.00M 10-K · filed 2021-03-26 | $2.03M 10-K · filed 2020-03-13 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 | $1.09M 10-Q · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $1.09M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | |||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |